scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET

Company Participants

PJ Kelleher - IR
John Tucker - CEO
Steve Parsons - SVP of Commercial
Rachael Nokes - CFO

Conference Call Participants

Glen Santangelo - Jefferies
Stacy Ku - TD Cowen
Roanna Ruiz - Leerink Partners
Chase Knickerbocker - Craig-Hallum Capital
Naz Rahman - Maxim Group
Douglas Tsao - HC Wainwright

Operator

Good afternoon, ladies and gentlemen, and welcome to the scPharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Also note that the call is being recorded Tuesday, May 14, 2024. And I would like to turn the conference over to PJ Kelleher, Investor Relations. Please go ahead.

PJ Kelleher

Thank you, operator. Before turning to call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws, including but not limited to statements regarding scPharmaceuticals’ expected future financial results, management's expectations and plans for the business, the ongoing commercialization and marketing of FUROSCIX, and the potential label expansion and other regulatory approval of FUROSCIX. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other important factors that may affect scPharmaceuticals business, financial condition, and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Any forward-looking statements made in this conference call, including responses to your questions, are based on current expectations as of today. And scPharmaceuticals expressively disclaims any intent or obligation to update these forward-looking statements except as required by law.

It is now my pleasure to turn the call over to Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?

John Tucker

Thank you, PJ. And thanks to everyone who has been at this afternoon's call and webcast to review our first quarter 2024 results. As has been our practice, I will begin with an operational update before turning the call over to Steve Parsons, our Senior Vice President of Commercial, for a more detailed commercial update on FUROSCIX, and then Rachael Nokes, our Chief Financial Officer, for a review of our financials. We will then open the call for your questions.